title: Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II randomized multicenter study).
abstract: The ACUTE II study demonstrated that transesophageal echocardiographically guided cardioversion with enoxaparin in patients with atrial fibrillation was associated with shorter initial hospital stay, more normal sinus rhythm at 5 weeks, and no significant differences in stroke, bleeding, or death compared with unfractionated heparin (UFH). The present study evaluated resource use and costs in enoxaparin (n=76) and UFH (n=79) during 5-week follow-up. Resources included initial and subsequent hospitalizations, study drugs, outpatient services, and emergency room visits. Two costing approaches were employed for the hospitalization costing. The first approach was based on the UB-92 formulation of hospital bill and diagnosis-related group. The second approach was based on UB-92 and imputation using multivariable linear regression. Costs for outpatient and emergency room visits were determined from the Medicare fee schedule. Sensitivity analysis was performed to assess the robustness of the results. A bootstrap resample approach was used to obtain the confidence interval (CI) for the cost differences. Costs of initial and subsequent hospitalizations, outpatient procedures, and emergency room visits were lower in the enoxaparin group. Average total costs remained significantly lower for the enoxaparin group for the 2 costing approaches ($5,800 vs $8,167, difference $2,367, 95% CI 855 to 4,388, for the first approach; $7,942 vs $10,076, difference $2,134, 95% CI 437 to 4,207, for the second approach). Sensitivity analysis showed that cost differences between strategies are robust to variation of drug costs. In conclusion, the use of enoxaparin as a bridging therapy is a cost-saving strategy (similar clinical outcomes and lower costs) for atrial fibrillation.
authors.affiliation: Emory University, Atlanta, Georgia, USA. lzhao2@emory.edu
authors.forename: Liping
authors.initials: L
authors.lastname: Zhao
authors.forename: Zefeng
authors.initials: Z
authors.lastname: Zhang
authors.forename: Paul
authors.initials: P
authors.lastname: Kolm
authors.forename: Susan
authors.initials: S
authors.lastname: Jasper
authors.forename: Cheryl
authors.initials: C
authors.lastname: Lewis
authors.forename: Allan
authors.initials: A
authors.lastname: Klein
authors.forename: William
authors.initials: W
authors.lastname: Weintraub
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000191:economics* / Q000628:therapy; D003365:Costs and Cost Analysis; D017548:Echocardiography, Transesophageal; D004554:Electric Countershock; D017984:Enoxaparin / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use; D006296:Health Services / Q000706:statistics & numerical data; D006493:Heparin / Q000191:economics* / Q000627:therapeutic use; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D006278:Medicare / Q000191:economics; D008875:Middle Aged; D012107:Research Design; D018084:Ultrasonography, Interventional; D014481:United States
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006493:Heparin